- Global Operation
- Contract Manufacturing
Quinoflox®‚ is a preparation of Sparfloxacin. It is a broad-spectrum antibacterial agent that inhibit DNA gyrase and topoisomerase IV and kills many of the types of bacteria that can infect the breathing airways and lungs and has been shown in a large number of clinical trials to be safe and effective for the treatment of bacterial infections. It is found to be more effective in vitro than other fluoroquinolones against some gram positive organisms (Streptococcus pneumoniae, Staphylococcus aureous,), Mycobacteria and Chlamydia spp.
Quinoflox® (sparfloxacin) is indicated for the treatment of adults (>/= 18 years of age) with the following infections caused by susceptible strains of the designated microorganisms:
Community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Mycoplasma pneumoniae , or Streptococcus pneumoniae.
Acute bacterial exacerbations of chronic bronchitis (ABECB) caused by Chlamydia pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Staphylococcus aureus , or Streptococcus pneumoniae.
It is also indicated for
*Chronic Obstructive Pulmonary Disease (COPD)
*Acute Maxillary Sinusitis (AMS)
*Urinary tract infections including gonococcal and nongonococcal urethritis, chancroid and other sexually transmitted diseases.
Other uses include treatment of tuberculosis in combination with rifampicin and isoniazid, treatment of leprosy in combination with standard drugs.
Quinoflox® 200mg Tablet: Box containing 1 strip of 10 tablets.